



OHDSI APAC Symposium

Thank you for joining the Journey!

Patrick Ryan, PhD

Vice President, Observational Health Data
Analytics, Janssen Research and Development

Assistant Professor, Adjunct, Department of
Biomedical Informatics, Columbia University
Irving Medical Center



OHDSI APAC 2020 Symposium Agenda

Korean Time OHDSI APAC 2020 Session and Title - Dec 5th

10:00 - 10:30 OHDSI Welcome Session

10:30 - 11:30 Panel – OHDSI Community in Action – COVID19 Global effort

11:30 - 12:30 Network Session

12:30 - 13:30 APAC Study - Comprehensive comparative effectiveness and safety of second line antihypertensive agents; utilising the LEGEND principles to mobilize collaboration across the OHDSI APAC network

13:30 - 14:00 DOAC Study - Comparative effectiveness and safety of direct ORal Anticoagulants in patients with atrial fibrillation: a standardiZed Observational data Network study (CORAZON)

Korean Time OHDSI APAC 2020 Session and Title - Dec 6th

10:00 - 10:30 OHDSI APAC State of the Community

10:30 - 13:00 OHDSI Chapter Breakout – China/Hong Kong, Australia, Singapore, Korea, Taiwan, Japan

13:00 - 13:30 Fun with the Community

13:30 - 14:00 Closing Ceremony



COLLABORATOR SHOWCASE - POSTERS

Name	Affiliation	Poster
Zachary Monge	Covance	A Hybrid Statistical-Machine Learning Approach to Anomaly Detection in Clinical Trial Data
Ty Stanford	University of South Australia	Mapping to standardised vocabularies: a process for drug codes in Australia
Guy Tsafnat	Evidentli	AI-powered data mapping
Jason C. Hsu	Taipei Medical University	Taipei Medical University Clinical Research Database (TMUCRD): A New Application Platform that Integrates Multi-center Electronic Medical Record Systems in Taiwan
Gang Wang	Beijing Anding Hospital affiliated to Capital Medical University	Treatment Patterns and Risk of Switch to Mania in Bipolar Depressive Patients Treated with Antidepressants: A real world study using the OHDSI Network
Gang Wang	Beijing Anding Hospital affiliated to Capital Medical University	Transforming the Psychiatric Hospital Database to the OMOP Common Data Model in China
Preetham Kadappu	School of Medical Sciences, University of New South Wales	Statin Prescribing Patterns and Residual CRP Risk on Hospitalisation in a South-Western Sydney Population

<https://www.ohdsi.org/2020-asia-pacific-symposium-collaborator-showcase/>



OHDSI

OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

- Who We Are ▾
- OHDSI Updates & News ▾
- Standards
- Software Tools
- OHDSI Studies
- Book of OHDSI ▾
- Resources ▾
- New To OHDSI? ▾
- EHDEN Academy ▾
- 2020 Global Symposium ▾**
- 2020 APAC Symposium ▾
- Past Events
- OHDSI in MTeams ▾
- Social Media/Newsletter ▾

[Home](#) > 2020 OHDSI Global Symposium

2020 OHDSI Global Symposium

The 2020 OHDSI Global Symposium brought together a global research community for 18 hours of open science, international collaboration and community fun on Oct. 19. The day included presentations from community members, panels that brought together leaders from a variety of major healthcare organizations, as well as network sessions, the annual collaborator showcase, and plenty more. Please check out this page for complete updates from the day, and follow the OHDSI Twitter and LinkedIn feeds for the #OHDSISocialShowcase, which will highlight all presentations from the 2020 Collaborator Showcase.

The four-day event also included five virtual tutorials on Oct. 18, and a two-day study-a-thon (Oct. 20-21) that focused on two cardiovascular clinical prediction models (CPM) routinely used in clinical practice: the Revised Cardiac Risk Index (RCRI) and the Pooled Cohort Equations. That collaborative effort set the foundation for multiple network studies [on these important healthcare issues](#).

Global Symposium Sessions

<https://www.ohdsi.org/2020-ohdsi-global-symposium/>



Symposium artwork courtesy of OHDSI collaborator Sarah Seager.

Collaborator Showcase:

- 85 posters
- 10 software demos
- 12 lightning talks



Clinical Trial Data Conventions for the OMOP CDM

PRESENTERS

Chris Roeder, Katy Sadowski, Maxim Moinat, Philip Solovyev, Sonia Araujo

INTRO

- The current OMOP CDM was created for observational health data.
- A significant gap exists in representing many of the distinctive features of clinical trial data.

METHODS

- We advocate for minimal changes to the OMOP CDM and Standardized Vocabularies whilst providing a value-add SDTM-to-OMOP conversion to capture the unique elements of clinical trial data.
- We are focusing first on converting clinical trial data in CDISC SDTM format.

RESULTS

- We propose to create one observation period record only per clinical trial subject.
- We covered 8 main topics – from trial information and visits, to type concept ids – for which there is currently insufficient support in the OMOP CDM and Standardized Vocabularies.

CONCLUSIONS & NEXT STEPS

- We submitted our proposal to the OHDSI community in July 2020 for review and leadership approval.
- Mapping clinical trial data to the OMOP CDM potentially will add a large volume of data to the OHDSI ecosystem and allow observational and trial data to be combined in analyses.
- We are applying the proposed conventions to a specific clinical trial in CDISC SDTM format to gain further insight into the process of mapping SDTM data to OMOP.
- We welcome new members to this working group!

The OHDSI Clinical Trial Working Group proposes conventions to represent clinical trial specific data with minimal changes to the existing OMOP CDM



Take a picture to connect to the OHDSI Clinical Trial Working Group wiki

OR connect at this [link](#)

PROPOSAL SUMMARY

Topic	Proposal Summary
Trial enrollment & trial outcomes	We propose to store these data as an observation for each event related to a person's trial status (e.g., informed consent or completion of trial).
Trial visits	We propose to extend OMOP CDM vocabularies to capture the different trial visit concepts across clinical trial epochs, and to have composite source values to capture time indicators within an epoch (e.g., TREATMENTWEEK 7).
Seriousness, severity and causality	We propose to link an observation or condition to another record to capture adverse events, along with their seriousness, severity and causality to the trial subject's drug or treatment, via oncology extensions (measurement modifiers) and Observation attributes from OMOP CDM v6.
Study information and arm assignment	We propose storing information about which trial arm the individual trial subjects are in using the COHORT table. We propose storing information about the trial design and trial arms in the COHORT_DEFINITION table.
Novel concepts	Some drugs cannot be standardized as they haven't been "seen" before. For drug concepts, single new concepts can be added without substantial effort at the ingredient level. We propose an improved and simplified process to add clinical drug level drug concepts as RxNorm extensions.
Type concept ids	Type concepts in OMOP give the provenance of a record. We propose to use the newly-added standard type concept for "Case Report Form" to represent trial provenance.
Planned drug dose	To keep administered and planned drug doses in a way that makes comparing them possible, we propose to use a type concept id in the DRUG EXPOSURE table that allows that distinction.
Relative dates	In some clinical trials e.g. when a trial is anonymized, events' timepoints are given as days offset from a subject's informed consent or randomization date. If relative dates are given, we propose to calculate dates using the subject's reference date. The METADATA table can be used to record dates are derived.

AUTHORS

Alexandra Orlova¹, Andrew Williams, PhD², Asiyah Yu Lin^{3,4}, Chris Roeder, MS⁵, Cynthia Sung, PhD FCP⁶, Emma Vos, MSc⁷, Gregory Klebanov, MSc⁸, Joshua F. Ransom, PhD⁹, Katy Sadowski, BS¹⁰, Maxim Moinat, MSc¹¹, Michael Kalfelz, MD¹², Mike Hamidi¹³, Philip Solovyev, PhD¹⁴, Rhonda Facile, MS¹⁵, Shawn Dolley, MBA¹⁶, Sonia Araujo, PhD¹⁷, Tom Walpole¹⁸, Vojtech Huser, MD PhD¹⁹

¹Odyssey, USA; ²Tufts Institute for Clinical Research and Health Policy Studies, USA; ³Center for Devices and Radiological Health, FDA, USA; ⁴National Center for Oncological Research, USA; ⁵University of Colorado, USA; ⁶Bill & Melinda Gates Medical Research Institute, USA; ⁷The Hyve, The Netherlands; ⁸REXHealth Inc, USA; ⁹TrialSpark, USA; ¹⁰CDISC, USA; ¹¹Eligo, USA; ¹²Open Global Health, USA; ¹³QVIA, UK; ¹⁴Trials.ai, USA; ¹⁵National Institutes of Health, USA



2020 Best Contribution in Observational Data Standards

Clinical trial data conventions for the OMOP Common Data Model
Chris Roeder, Katy Sadowski, Maxim Moinat, Philip Solovyev, Sonia Araujo, et al.



Noisy-Or Risk Allocation: A Probabilistic Model for Attributable Risk Estimation

Amelia J. Averitt, MPH MA PhD^{1,2}; Adler Perotte, MD MA¹


¹ Columbia University, Department of Biomedical Informatics. New York, NY. ² Regeneron Genetics Center. Tarrytown, NY.

Introduction

Attributable risk (AR) is the proportion of an outcome in a population that could be prevented by elimination of a causal exposure from the population [1]. In the high-dimensional setting, typical methods of AR estimation include the (i) calculation of excess risk [2]; (ii) approximation using disproportionality methods, such as risk ratios (RR) and Gamma Poisson Shrinker (GPS); and (iii) regression-based methods. However, none of these methods are able to estimate global ARs, predict outcomes, and estimate ARs of exposures at the individual-level.

This research proposes the Noisy-Or Risk Allocation (NORA) model for high-dimensional AR estimation from observational data. NORA is a multivariate, latent-variable model with a likelihood that captures the notion of causal independence. Unlike comparator methods, NORA supports both global inferences of risks and local inferences of risks and outcomes.

The Model



K = The number of exposures (1)

N = The number of subjects (2)

$Z_{n,k}|X_{n,k}, R_k \sim \text{Bernoulli}(X_{n,k}R_k)$ (3)

$R_k|\alpha, \beta \sim \text{Beta}(\alpha, \beta)$ (4)

$p(Y_n|Z_{1:K}) \sim \text{Bernoulli}(1 - \prod_{k=1}^K (1 - Z_{n,k}))$ (5)

Key Takeaways

- NORA infers ARs of causal exposures for a single binary outcome.
- Simulations suggest that NORA may be more robust to confounding than logistic regression.
- NORA may support causal reasoning at the patient-level with outcome predictions and causal estimation and at the population-level informing public-health with estimates of risks across the entire population.

Simulation

To assess correctness the extent to which NORA is robust to bias, we simulated a confounded causal system for Myocardial Infarction (see file in MS Teams) in which the true risk (highest) is High Cholesterol (HC). NORA and L1 logistic regression (L1) were applied to learn ARs in the presence of observed and unobserved confounders.

Table 1: Estimated Risk of High Cholesterol by Model (True=0.30)

	Unobserved Confounders	Observed Confounders	% Bias
NORA	0.18	0.30	37.1%
L1	0.46	0.82	78.9%

Experimentation

We additionally applied NORA to 10 outcome-exposure cohorts from the NewYork-Presbyterian EHR (see Table 2 for outcomes). ARs were estimated for these causal systems using (i) NORA; (ii) L1; (iii) excess risk by Levin 1953; (iv) RR; and (v) GPS. We conducted a 3-part evaluation.

(1) **Local inference of the outcome** was evaluated through the predictive performance of a held-out dataset (NORA and L1 only.) The results (Table 2) indicate that NORA has competitive predictive ability to L1.

Table 2: Area Under the Receiver Operating Curve for NORA and L1

	DIC	Glaucoma	Hearing Loss	Heart Failure	Kaposi sarc.	Maculitis (v drug)	Renal Imp.	D/O Spleen	Hypothyroidism	Maculitis (v proc.)
NORA	0.89	0.70	0.51	0.80	0.80	0.53	0.82	0.65	0.56	0.59
L1	0.78	0.70	0.63	0.80	0.56	0.66	0.80	0.50	0.64	0.61


(2) **Global inference of the exposures** was evaluated by comparing the gold-standard, real-world AR of HIV for the outcome of Kaposi sarcoma [3] with the model-based AR estimates from NORA and comparators. Only NORA yielded an AR estimate in the correct order of magnitude (Table 3).

Table 3: AR Estimates of HIV for Kaposi sarcoma

	Gold-Standard	NORA	L1	Levin 1953	RR	GPS
HIV	0.0048	0.0070	0.7872	0.2022	0.9566	0.9603

(3) **Local inference of the exposures** was evaluated with an inspection of ARs & exposures for one individual with heart failure (HF). The posterior distribution over Z_n determines the probability that an exposure is a cause of the outcome given the remaining latent variables. The NORA-estimated high-AR exposures are known risk-factors of HF and are biologically sensible.

Figure 1: The Average AR of Exposures for a Single HF Patient



Funding acknowledgement: R01LM009886-10 and T15LM007079

[1] Leviton, A. Definitions of Attributable Risk. *Am J Epidemiol Sep 1;98(3):231-231. (1973).*
[2] Levin, M.L. The Occurrence of Lung Cancer In Man. *AJCC, 9, 531-541. (1953).*
[3] Liu Z, et al. The world-wide incidence of ... *HIV Med, 19(5):355-64. (2018).*

Noisy-Or Risk Allocation: A Probabilistic Model for Attributable Risk Estimation
Amelia Averitt, Adler Perotte



Large-scale evaluation of treatment effect heterogeneity in hypertension

Alexandros Rekkas¹, David van Klaveren¹, Peter R. Rijnbeek¹
Erasmus University Medical Center, Rotterdam, The Netherlands



Background

- Overall treatment effect estimates derived from the LEGEND-Hypertension study may not apply similarly to all individual patients
- As conventional subgroup analyses fail to capture the multivariate nature of heterogeneity of treatment effect (HTE), we opt for a risk modeling approach
- Outcome risk is a summary score that determines treatment effect—unlike individual variables that may or may not modify treatment effect
- We have developed a standardized easily scalable framework that enables risk-based assessment of HTE within the OHDSI paradigm
- Our work builds upon existing tools in the OHDSI Methods Library and previous work carried out during the LEGEND-Hypertension study

Methods

Databases

- IBM MarketScan® Medicare Supplemental Database (MDCR)
- IBM MarketScan® Commercial Database (CCAE)

Cohorts

Cohort definitions of the LEGEND-Hypertension study were used for both treatments and outcomes. We focus on the comparison of new users of ACE inhibitors to 4 other major classes of antihypertensive treatments:

- Angiotensin receptor blockers (ARB)
- Beta blockers
- Calcium channel blockers (CCB)
- Diuretics

We evaluated treatments regarding 55 outcome cohorts, including both main hypertension outcomes and safety outcomes.

Framework

The framework consists of six distinct steps:

- Definition of the problem, i.e. the population the treatment, the comparator and the outcome(s)
- Selection of the databases and the patient population
- Development of prediction models for the outcome(s) of interest
- Estimation of propensity scores within strata of predicted risk
- Estimation of relative and absolute treatment effects within strata of predicted risk
- Evaluation and presentation of the results

We have implemented the suggested framework in a publicly available R-package (<https://github.com/OHDSI/RiskStratifiedEstimation>).

Results

Table: Treatment cohort sizes in which our framework was applied

Treatment	MDCR	CCAE
ACE inhibitors	102,840	883,610
ARBs	32,275	274,368
Beta blockers	74,056	449,396
CCBs	50,088	311,032



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.




Figure: Absolute risk reduction of treatment with ACE inhibitors compared to treatment with the other 4 treatment classes. The comparisons were made in strata of predicted risk for hospitalization with heart failure. Positive values favor ACE inhibitors.

When comparing ACE inhibitors to calcium channel blockers LEGEND-Hypertension study found a calibrated hazard ratio of 0.85 (95% CI = [0.72, 1.03]) in CCAE database. However, the absolute benefit is concentrated in the highest risk group (top left graph), while the rest of the population receives no absolute benefit. This trend, can be seen in MDCR as well. Similar conclusions can be drawn in the case of beta blockers (top left, top right and bottom left graphs). ACE inhibitors may be unattractive for patients at lower risk of hospitalization with heart failure, because cough risk substantially increases with ACE inhibitors (bottom right graph). At the same time, heart failure rates are similar for both beta blockers and calcium channel blockers compared to ACE inhibitors.

A subset of our analyses can be explored by following the QR code.



Conclusions

Our framework for risk-based assessment of HTE is highly scalable and can be used to generate large amounts of evidence in a standardized and timely manner.

We aim to expand our analyses in both the direction of treatments compared, and databases considered, thus generating a vast amount of evidence that can better inform medical decision-making in hypertension.

Limitations: (1) Our method does not provide individualized estimates of treatment benefit, as we are still relying on subgroups; (2) Residual confounding is not evaluated within risk subgroups.

Contact: a.rekkas@erasmusmc.nl

Large-scale evaluation of treatment effect heterogeneity in hypertension
Alexandros Rekkas, David Van Klaveren, Peter Rijnbeek

2020 Best
Contribution in
Open-source
analytics
development



2020 OHDSI Symposium

2020 Best
Contribution in
Clinical
Applications



Lightning Talk: OHDSI Alexa Skill for a Personalized
COVID-19 Outcomes Risk Calculator

Lisa K. Evans, Baldwin School

<https://www.youtube.com/watch?v=jlErWf0h2KU>



OHDSI is
an open science community




OHDSI's mission

To improve health by empowering a community to collaboratively generate the evidence that promotes better health decisions and better care



The journey to real-world evidence






Odyssey (*noun*): \oh-d-si\

1. A long journey full of adventures
2. A series of experiences that give knowledge or understanding to someone



My ongoing journey across the Asia-Pacific region


ICPE 2013
Montreal Canada



ACPE 2013
Hong Kong



OHDSI Korea 2017
Suwon, Korea



ICPE 2014
Taiwan



OHDSI Korea 2019
Gwangju, Korea



OHDSI Fudan 2019
Shanghai, China




OHDSI APAC 2020
EVERYWHERE!















OHDSI community

We're all in this journey together...





OHDSI
OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

COVID-19 Study-A-Thon

ohdsi.org/covid-19-updates

Shabbir Syed Abdul
Aaron Aband
Tereza Abrahao
Amanda Alberg
Heba Alghoul
Munth Alser
Osaid Alser
Thamir Alshammari
Min Ho An
Alan Andryc
Miguel Angel Mayer
Katherine (Linda) Arapa
Carlos Areia
George Argyriou
Alex Asimovic
Oliver Baele
Charles Bailey
Juan Banda
Julio Barbour
Dave Barman
Sarah Baermeister
Patricia Biedermann
Belay Birie Yimer
Adam Black
Clair Blacketer
Rebecca Brown
Kate Bryan
Theresa Burkard
Wynn Burko
Edward Burn
Geert Byttebier
Pasquale Cacciatore
Martin Campodonico
Jose Manuel
Cancio Trujillo
Paula Camajest
Wang Changran
Vivek Charu
Ray Chen
Ricky Chen
Jashyeong Cho
Sylvia Cho
Young June Choe
Youn Choi
YunChang Choi

Eric Chung
Christopher Chute
Liliana Cioaba
Mitch Conover
Paul Coplan
Aedin Cullane
Raghava Dandawa
Courtney Davis
Alex Davydov
Marta de Ridder
Ellen de Waal
Marcel de Wilde
Rodrigo DeAntonio
Frank DeFalco
Paul-Oliver Dehaye
Sara Dempster
Freja Descamps
Nafecsa Dhalwai
Rachael DiSantostefano
Hung Do
S. Dong
Iannis Drake
Joseph Drozda
Telita Duarte Salles
Jon Duke
Scott Duval
Dmitry Dymshyts
Noemie Elhadad
Noah Engel
John Esposito
Lee Evans
Thomas Falconer
Margarita Fernandez-Chas
Brian Fisher
Kristina Flister
Stephen Fortin
Luca Foschini
Frank Fox
Darwin Fu
Gang Fu
Weihsiao Gao
Xavier Garcia Cusco
Maria Teresa
Garcia Morales
Zeshan Ghory

Undina Gialdottir
Mikhail Gogenur
Jose Felipe Gofin Ozib
Anish Gotozar
Lisa Gonzales
Artem Gorbochev
David Gatz
Anna Graber
Denis Granados
Birgitta Grundmark
Melissa Hoesdel
Lars Halvorsen
Jill Hardin
Rune Petring Hasselager
Oscar Hayes
Waili He
Ying (Helen) He
Yongqun Oliver He
Karin Hedenmalm
Boris Hejblum
Louis Hendriks
Ronald Herrera
Laura Hester
Ha Hong
Stephanie Hung
Ji Hongquan
Michelle Hribar
George Hripcaak
Marc Hsu
Hao Hu
Chao Hua
Nigel Hughes
(unknown) Huilin
Vojtech Huser
(unknown) Hyeon
Solomon Ioannou
Usman Iqbal
William Jang
Geyanandan Jebadurai
Yuxi Jia
Yuxi Jia
Yonghua Jing
Henrik John
Beverly Johns
Kim Jaehyun







Kim Jung Ae
Tae Hyun Jung
Dany Kaduk
Linda Kalliani
Michael Kalifetz
Rajesh Kamalakar
Akhil Karamia
Prasanna Lakshmi
Kandukuri
Seamus Kent
Sajan Khosla
Eanna Kiley
Chungsoo Kim
Jenny Yeon Hye Kim
Seok Kim
Yeesuk Kim
Grig Klabanov
Juliana Kohler
Spyros Koloves
Edik Korchmar
Jan Kora
Tess Korthout
Kristin Kootka
Norbert Kremer
Steve Kundrot
Rintu Kutum
Sanggyu Kwak
K Lakshmi
Christophe Lambert
Chris Lane
Jennifer Lane
Geunhan Lee
Seungwon Lee
Alan Burton Lenarcic
Bennett Levitan
Michael Li
Asiyah Lin
George Linderman
Ying Liu
Ajit Lodhe
Esteban Londoio
Jim Long
Kristine Lynch
Gerardo Machnicki
R Maheswari

Rupa Makadia
Susan Mallik
Shivaji Mantlana
Andres Margulis
Anish Markus
Michael Matheny
Andrew McKinnon
James McMorran
Paras Mehta
Gong Mengchun
Swarna Menon
Evan Minty
Shazia Mishra
Maxim Moinat
Zach Moldwin
Daniel Morales
Ester Morales
Henry Morgan Stewart
Hees Monseveld
Rajeev Nagpal
Surbit Nagpal
Karthik Natarajan
Danielle Newby
Ryan Nguyen
Akiko Nishimura
Fredrik Nyberg
Keith O'Rourke
Richard Oteri-Asensio
Iredia Olaye
Carmen Olga-Torres
Dr. Olwi
Anna Ostropelets
Susana Otvor
Helen Pal
Matvey Palchuk
Miao Panpan
Miriam Pappas
Jinyung Park
Kyoung Sik Park
Rae Woong Park
Youn Park
S Parthiban
Alan Passley
Dany Patel
Nataly Patino

Eugene Paulenkovich
Melanie Philofsky
Robin Pierce
Luis Pinheiro
Tamara Polus
Jose Posada
Jelle Praet
Albert Prats-Uribes
Nicole Pratt
Daniel Prieto-Alhambra
Sanjay Purushotham
Ye Qing
Matiur Rahman
Gowtham Rao
Shilpa Ratwani
Daniel Razzaghi
Martina Recalde
Christian Reich
Ines Reinecke
Jenna Reps
Josie Reynolds
Sang Youl Rhee
Sandy Rhie
Peter Rijnbeek
Marcelo Rivera
Amy Roach
Mitro Rocca
M Rubel
Samuel Rubinstein
Stacy Russ
Patrick Ryan
Craig Sachson
Paola Scarofim
Selva Sathappan
Lisa Schilling
Judeen Schneider
Andreu Schoonenberger
Lopez
Martijn Schamie
Sarah Seeger
Tom Seinen
Anthony Sena
Alexia Sentia
unknown Sejeong
Seko Setoguchi

Michael Shamberger
Yong Shang
Jindia Shi
Azra Shoolbi
Siddhartha Shrivastava
Anastasio Siliacos
Alexander Sivira
Benjamin Skov
Kees-Mann
Kathleen Smith
Robert Snijder
Yi Soyoung
Matthew Spotsitz
Sesh Srinivasan
Jennifer Stacey
Ty Stanford
Paul Stang
Ewout Steyerberg
Marc Storchard
Cynthia Sung
Sunkey
Marshall Sutton
Joel Swerdel
J Swetha
Ana Szarfman
Zolt Szekeres
Polina Talapova
Nick Tatoneiti
Cristian Tebe Cordoni
Phyllis Thangaraj
Siva Thotapalli
Yakui Tian
Annalisa Trama

Guy Tsafnat
Adamantia Tzoucharika
Mark Samuel Tuttle
Neas Valvany
David Van Brunt
Johan van der Lei
Muel Van Zandt
Jesus Vazquez
David Vizcaya
Joshua Vogelstein
Sal Volpe
Kees von Rochove
Emma Vos
Bridget Wang
Siting Wang
Yilun Wang
Zhixiao Wang
Jania Weaver
Wu Wei
Rachel Weinstein
Haini Wen
Chunhua Wong
Thomas White
Marsha Wilcox
Andrew Williams
Ross Williams
Jennifer Wilson
Traci Wolbert
Hyunki Woo
Kristin Wroblewski
Wendi Wu
Wang Xiaolin
Hui Xing



OHDSI COVID-19 Study-a-Thon (3/2020)



Snapshot of the OHDSI COVID-19 Data Network



USA (11)	EUROPE (8)	ASIA-PACIFIC (3)
Columbia University (NY – EHR)	CPRD (UK – EHR)	HIRA (South Korea – Administrative Claims)
Department of Veterans Affairs (National – EHR)	DA Germany (Germany – EHR)	DCMC (South Korea – EHR)
HealthVerity (Claims linked to diagnostic testing)	HM Hospitales (Spain – Hospital Billing)	Nanfang Hospital (China – EMR)
IQVIA Open Claims (National – Administrative Claims)	IPCI (Netherlands – EHR)	
Optum EHR (National – EHR)	LPD France (France – EHR)	
Optum SES (National – administrative claims)	LPD Italy (Italy – EHR)	
Premier (National – Hospital Billing)	SIDIAP (Spain – EHR)	
Stanford University (CA – EHR)	SIDIAP-H (Spain – EHR Hospital linkage)	
Tufts University (MA – EHR)		
University of Colorado Anschutz Medical Campus (CO – EHR)		
University of Washington Medicine COVID Research Dataset (WA – EHR)		

Together, OHDSI has studied:

- **>7.4m** patients tested for SAR-COV-2
- **>1.6m** patients diagnosed or tested positive for COVID-19
- **>300k** patients hospitalized with COVID-19



Characterization

CHARYBDIS Results Viewer

Interactive application for exploring disease natural history:

- <https://data.ohdsi.org/Covid19CharacterizationCharybdis/>

The image displays four overlapping screenshots of the medRxiv preprint server interface, which is part of the CHARYBDIS Results Viewer. Each screenshot shows a paper title, authors, and a 'Comment on this paper' link. The papers are:

- Top Left:** "Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study". Authors: Talita Duarte-Salles, David Vizcaya, Andrea Pistillo, Paula Casajust, Anthony G. Sena, Lana Yin Hui Lai, Albert Prats-Urbe, Waheed-UI-Rahman Ahmed, Thami M Alshammari, Heba Alghoul, Osaïd Alser.
- Top Right:** "Heterogeneity and temporal variation in the management of COVID-19: a multinational drug utilization study including 71,921 hospitalized patients from China, South Korea, Spain, and the United States of America". Authors: Albert Prats-Urbe, Anthony G. Sena, Lana Yin Hui Lai, Waheed-UI-Rahman Ahmed, Heba Alghoul, Osaïd Alser, Thami M Alshammari, Carlos Areia, William Carter, Paula Casajust, Dalia Dawoud, Asieh Golozar, Jitendra Jonnagaddala, Paras Mehta, Gong Mengchung, Daniel R Morales, Fredrik Nyberg.
- Bottom Left:** "Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis". Authors: Lana Yin Hui Lai, Asieh Golozar, Anthony Sena, Andrea V. Margulis, Nuria Haro, Paula Casajust, Neus Valeny, Albert Prats-Urbe, Evan P. Minty, Waheed-UI-Rahman Ahmed, Thami M Alshammari, Daniel R. Morales, Heba Alghoul, Osaïd Alser, Dalia Dawoud, Lin Zhang, Jose D. Posada, Nigam H. Shah, Clair Blacketer, Carlos Areia, Vignesh Subbian, Fredrik Nyberg, Jennifer C. E. Lane, Marc A. Suchard, Mengchun Gong, Martina Recalde, Jitendra Jonnagaddala, Karishma Shah, Elena Roel, David Vizcaya, Stephen Fortin, Ru-fong Joanne Cheng, Christian Reich, George Hripcsak, Peter Rijnbeek, Patrick Ryan, Kristin Kostka, Talita Duarte-Salles, Daniel Prieto-Alhambra.
- Bottom Right:** "Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom". Authors: Martina Recalde, Elena Roel, Andrea Pistillo, Anthony G Sena, Albert Prats-Urbe, Waheed UI-Rahman Ahmed, Heba Alghoul, Thami M Alshammari, Osaïd Alser, Carlos Areia, Edward Burn, Paula Casajust, Dalia Dawoud, Scott L DuVall, Thomas Falconer, Sergio Fernandez-Bertolin, Asieh Golozar, Mengchun Gong, Lana Yin Hui Lai, Jennifer C.E. Lane, Kristine E Lynch, Michael E Matheny, Paras P Mehta, Daniel R Morales, Karthik Natarajan, Fredrik Nyberg, Jose D Posada, Christian G Reich, Lisa M Schilling, Karishma Shah, Nigam H Shah, Vignesh Subbian, Lin Zhang, Hong Zhu, Patrick Ryan, Daniel Prieto-Alhambra, Kristin Kostka, Talita Duarte-Salles.



Prediction

COVER: COVID risk prediction

Interactive application for exploring prediction:

- <https://data.ohdsi.org/Covid19CoverPrediction/>



<https://www.ohdsi.org/2020-ohdsi-global-symposium/>



Research

JAMA | **Original Investigation**

Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Seng Chan You, MD, MS; Yeunsook Rho, PhD; Behnood Bikdeli, MD, MS; Jiwoo Kim, MS; Anastasios Siapos, MSc; James Weaver, MSc; Ajit Londhe, MPH; Jaehyeong Cho, BS; Jimyung Park, BS; Martijn Schuemie, PhD; Marc A. Suchard, MD, PhD; David Madigan, PhD; George Hripcsak, MD, MS; Aakriti Gupta, MD, MS; Christian G. Reich, MD; Patrick B. Ryan, PhD; Rae Woong Park, MD, PhD; Harlan M. Krumholz, MD, SM

IMPORTANCE Current guidelines recommend ticagrelor as the preferred P2Y₁₂ platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in routine practice merits attention.

OBJECTIVE To determine the association of ticagrelor vs clopidogrel with ischemic and hemorrhagic events in patients undergoing percutaneous coronary intervention (PCI) for ACS in clinical practice.

DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study of patients with ACS who underwent PCI and received ticagrelor or clopidogrel was conducted using 2 United States electronic health record–based databases and 1 nationwide South Korean database from

← Editorial page 1613

← JAMA Patient Page page 1690

+ Audio and Supplemental content

+ CME Quiz at jamacmelookup.com and CME Questions page 1672



Bergabunglah dengan Journey!

여정에 참여하세요!

加入旅程！

เข้าร่วมการเดินทาง!

Join the Journey!

旅に参加しましょう！

Tham gia Hành trình!

加入旅程！

यात्रा में शामिल हों!

Sumali sa Paglalakbay!

Yolculuğa Katılın!

ਯਾਤਰਾ ਵਿਚ ਸ਼ਾਮਲ ਹੋਵੋ!